OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Fernandez on the Utility of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

December 22nd 2021

Aileen I. Fernandez, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Dr. Danila on Examining Immunotherapy in Early-Stage Prostate Cancer

December 22nd 2021

Daniel C. Danila, MD, discusses the rationale for examining immunotherapy in early-stage prostate cancer.

Dr. Ghia on the Design of the CAPTIVATE Study in Treatment-Naïve CLL

December 22nd 2021

Paolo Ghia, MD, PhD, discusses the design of the phase 2 CAPTIVATE study in treatment-naïve chronic lymphocytic leukemia.

Dr. Hurvitz on the Key Objectives of DESTINY-Breast03 in HER2+ Breast Cancer

December 21st 2021

Sara A. Hurvitz, MD, discusses the rationale for the phase 3 DESTINY-Breast03 trial examining in HER2-positive breast cancer.

Dr. Heyman on Ibrutinib Plus Venetoclax in Relapsed/Refractory MCL

December 21st 2021

Benjamin Heyman, MD, discusses the phase 3 SYMPATICO trial examining the combination of ibrutinib and venetoclax vs ibrutinib alone in patients with relapsed or refractory mantle cell lymphoma.

Dr. Dorff on the Clinical Implications of the ARAMIS Trial in Nonmetastatic CRPC

December 21st 2021

Tanya Dorff, MD, discusses the clinical implications of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Dr. Seymour on the Design of the ELEVATE-RR Trial in Relapsed/Refractory CLL

December 21st 2021

John F. Seymour, MBBS, FRACP, PhD, discusses the design of the phase 3 ELEVATE-RR trial comparing acalabrutinib vs ibrutinib in chronic lymphocytic leukemia.

Dr. Jain on the Importance of Communication for Multidisciplinary Care in CRC

December 21st 2021

Shikha Jain, MD, FACP, discusses the importance of communication in patients with colorectal cancer and liver metastases who are receiving multidisciplinary care.

Dr. Riedell on the Effects of Time to Relapse on Outcomes in MCL

December 21st 2021

Peter Riedell, MD, discusses the effects of time to relapse on outcomes in mantle cell lymphoma.

Dr. Kremyanskaya on the Design of the MANIFEST Trial in Myelofibrosis

December 21st 2021

Marina Kremyanskaya, MD, PhD, discusses the design of the phase 1/2 MANIFEST trial in myelofibrosis.

Dr. Shirasu on the Clinical Implications of ctDNA in CRC

December 20th 2021

Hiromichi Shirasu, MD, discusses the clinical implications of the GALAXY trial as part of the CIRCULATE-Japan project, which is investigating circulating tumor DNA status in patients with resectable colorectal cancer.

Dr. Gomella on Novel Biomarker Research in Prostate Cancer

December 20th 2021

Leonard G. Gomella, MD, discusses ongoing studies evaluating novel biomarkers in prostate cancer.

Dr. Zurita-Saavedra on Leveraging Antiandrogen Agents in Metastatic HSPC

December 20th 2021

Amado J. Zurita-Saavedra, MD, discusses the utilization of the antiandrogen agents apalutamide and enzalutamide in patients with metastatic hormone-sensitive prostate cancer.

Dr. Ciombor on the Utilization of Maintenance Panitumumab in RAS Wild-Type Metastatic CRC

December 20th 2021

Kristen K. Ciombor, MD, MSCI, discusses the use of panitumumab in the maintenance treatment of patients with RAS wild-type metastatic colorectal cancer.

Dr. Hubbard on the Design of the NRG-GI005 Trial in Colorectal Cancer

December 17th 2021

Joleen M. Hubbard, MD, discusses the design of the ongoing phase 2/3 NRG-GI005 trial in patients with stage IIA colorectal cancer after surgery.

Dr. Sood on Navigating Frontline Maintenance Therapy in Ovarian Cancer

December 17th 2021

Anil K. Sood, MD, discusses navigating frontline maintenance therapy in ovarian cancer.

Dr. Penson on PARP Inhibitors as Switch Maintenance Therapy in Recurrent Ovarian Cancer

December 17th 2021

Richard T. Penson, MD, MRCP, discusses selecting between PARP inhibitors for switch maintenance therapy in recurrent ovarian cancer.

Dr. Ghodoussipour on Trials of Cytoreductive Surgery in Metastatic RCC and Prostate Cancer

December 17th 2021

Saum Ghodoussipour, MD, discusses ongoing trials in renal cell carcinoma and prostate cancer.

Dr. Mouhieddine on Outcomes After Bispecific Antibodies in R/R Multiple Myeloma

December 17th 2021

Tarek H. Mouhieddine, discusses a study that evaluated outcomes in patients with relapsed/refractory multiple myeloma who progressed on bispecific antibodies.

Dr. Daver on the Next Steps for Menin Inhibitors in AML

December 17th 2021

Naval Daver, MD, discusses the next steps for menin inhibitors in acute myeloid leukemia.